Ketamine liquid formulations and uses thereof
By developing ketamine liquid preparations and using oral mucosa to administer drugs, the demand for esketamine hydrochloride nasal spray for poor tolerant patients is solved, reducing the risk of abuse and side effects, improving bioavailability and stability, and suitable for more depression Patients with symptoms.
Patent Information
- Application Number
- CN202410606412.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-22
AI Technical Summary
Existing esketamine hydrochloride nasal sprays cannot meet the needs of patients with inflammation or poor nasal mucosa when administered nasally, and due to high concentrations, the risk of ketamine abuse is increased, the bioavailability is low, and the absorption rate is fast. Poor absorption in the body.
Provide a ketamine liquid preparation, administered through oral mucosa, the formula includes 0.5% w/v to 8.5% w/v ketamine or its salt, combined with at least two lower alcohols and water, adopts a simple, stable and fast absorption formula, Contains tackifiers and flavoring agents for improved compliance.
It improves the bioavailability of ketamine, reduces the risk of abuse, reduces the irritation to the mucosa, enhances the stability and palatability of the drug, simplifies the drug administration process, is suitable for more patients with depression, and reduces the cost of treatment.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present application relates to, but is not limited to, the field of pharmaceutical preparation technology, and in particular to a ketamine liquid preparation and its use as an antidepressant drug. Background Art
[0002] Depression is a form of manic-depressive illness, with low mood, slow thinking, and reduced speech and slow movements as typical symptoms. Depression seriously troubles the patient's life and work, and brings a heavy burden to the family and society.
[0003] In recent years, ketamine has attracted much attention as a psychiatric drug for the treatment of depression, and a large number of reports have proven its antidepressant effect. As a fast-acting antidepressant, ketamine may achieve its antidepressant effect by increasing monoamine release or inhibiting presynaptic monoamine reuptake, thereby increasing the level of monoamine compounds in the brain.
[0004] Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist. Currently, most ketamine used in clinical practice is a racemic form, containing two enantiomers, namely dextrorotatory ketamine and levorotatory ketamine.
[0005] An antidepressant drug with a new mechanism developed by Johnson & Johnson in the United States is a nasal spray with esketamine hydrochloride as the main drug. The product has rapid, long-lasting and powerful therapeutic effects on patients with refractory depression and suicidal tendencies, and was approved for its first launch in the United States in March 2019.
[0006] Although esketamine has achieved a good antidepressant effect through nasal administration, nasal administration cannot meet the medicinal needs of patients with nasal inflammation or poor nasal mucosal tolerance; in addition, for the nasal spray preparations of esketamine hydrochloride that have been on the market, the volume of nasal administration is small. In order to achieve the therapeutic dose, the concentration of esketamine hydrochloride in the preparation is high, close to the water solubility saturation of esketamine. This high concentration of esketamine hydrochloride solution will increase the risk of ketamine abuse to a certain extent; furthermore, pharmacokinetic studies have found that esketamine is administered through nasal spray, and the drug absorption rate is fast, but the nasal spray administration has poor drug absorption in the body and low bioavailability. Therefore, in order to better expand the clinical application scope of ketamine in antidepressant, meet the needs of more patients with depression, reduce treatment costs, and reduce the burden on patients' families, it is urgent to consider other effective routes of administration. Summary of the invention
[0007] The present application provides a ketamine liquid preparation, which is administered via the oral mucosa. The preparation of the present application has a simple formula, high stability, rapid absorption, simple administration method and good compliance.
[0008] In a first aspect, the present application provides a ketamine liquid preparation for oral mucosal administration, which includes ketamine or a pharmaceutically acceptable salt thereof at a concentration of 0.5% w / v to 8.5% w / v, at least two lower alcohols, and water.
[0009] In one embodiment, ketamine can be the (S)-enantiomer of ketamine, or the (R)-enantiomer of ketamine. In another embodiment, the (S)-enantiomer of ketamine is also known as S-ketamine, esketamine, (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride, etc.; in another embodiment, the (R)-enantiomer of ketamine is also known as R-ketamine, (R)-ketamine, akeketamine, levoketamine, arketamine, d-ketamine, (2R)-2-(2-chlorophenyl)-2 (methylamino)cyclohexanone, etc.; in another embodiment, ketamine is a mixture of the (R)-enantiomer of ketamine and the (S)-enantiomer of ketamine, such as a mixture of the (R)-enantiomer of ketamine and the (S)-enantiomer of ketamine in equal molar ratios.
[0010] In one embodiment, the liquid preparation of the present application contains at least two lower alcohols, and the lower alcohols are selected from: C1-C6 fatty alcohols, such as ethanol, n-propanol, isopropanol, n-butanol, isobutanol, ethylene glycol, propylene glycol, glycerol, sorbitol, mannitol, butylene glycol, hexylene glycol, etc.
[0011] In the embodiments of the present application, the C1-C6 fatty alcohol specifically refers to an alcohol formed by connecting a hydroxyl group and a saturated fatty hydrocarbon group containing 1 to 6 carbon atoms.
[0012] In one embodiment, the liquid preparation of the present application comprises two lower alcohols, and the two lower alcohols are ethanol and glycerol (or glycerin).
[0013] In one embodiment, the liquid preparation of the present application comprises ethanol and glycerol, wherein the weight ratio of ethanol to glycerol is (0.5 to 100):1, preferably 3.95:1.32.
[0014] In one embodiment, the liquid preparation of the present application comprises two lower alcohols, and the two lower alcohols are sorbitol and glycerol (or glycerin).
[0015] In one embodiment, the liquid preparation of the present application comprises sorbitol and glycerol, wherein the weight ratio of sorbitol to glycerol is (0.5 to 100):1, preferably 4.8:1.32.
[0016] The ketamine liquid preparation described in the present application has high bioavailability. Therefore, the liquid preparation can be prepared as a product with a lower substance concentration, which can not only meet the prevention or treatment needs of clinical patients, but also avoid the risk of abuse caused by high-concentration administration. At the same time, the ketamine liquid preparation has good compatibility with saliva, reduces irritation to mucous membranes, and reduces drug side effects. In addition, the ketamine liquid preparation has good stability even in the absence of preservatives and / or antioxidants.
[0017] In one embodiment, the concentration of ketamine in the liquid preparation is 0.7% w / v to 8.4% w / v; in another embodiment, the concentration of ketamine in the liquid preparation is 1.4% w / v to 6.8% w / v; in yet another embodiment, the concentration of ketamine in the liquid preparation is 1.4% w / v to 6.4% w / v. In still another embodiment, the concentration of ketamine in the liquid preparation is 0.7% w / v, 0.8% w / v, 0.9% w / v, 1.0% w / v, 1.1% w / v, 1.2% w / v, 1.3% w / v, 1.4% w / v, 1.5% w / v, 1.6% w / v, 1.7% w / v, 1.8% w / v, 1.9% w / v, 2.0% w / v, 2.1% w / v, 2.2% w / v, 2.3% w / v, 2.4% w / v, 2.6% w / v, 2.7% w / v, 2.8% w / v, 2.9% w / v, 3.0% w / v, 3.1% w / v, 3.2% w / v, 3.3% w / v, 3.4% w / v 4% w / v, 2.5% w / v, 2.6% w / v, 2.7% w / v, 2.8% w / v, 2.9% w / v, 3.0% w / v, 3.1% w / v, 3.2% w / v, 3.3% w / v, 3.4 %w / v, 3.5%w / v, 3.6%w / v, 3.7%w / v, 3.8%w / v, 3.9%w / v, 4.0%w / v, 4.1%w / v, 4.2%w / v, 4.3%w / v, 4.4% w / v, 4.5% w / v, 4.6% w / v, 4.7% w / v, 4.8% w / v, 4.9% w / v, 5.0% w / v, 5.1% w / v, 5.2% w / v, 5.3% w / v, 5.4%w / v, 5.5% w / v, 5.6% w / v, 5.7% w / v, 5.8% w / v, 5.9% w / v, 6.0% w / v, 6.1% w / v, 6.2% w / v, 6.3% w / v, 6.4% w / v, 6.5% w / v, 6.6% w / v, 6.7% w / v, 6.8% w / v, 6.9% w / v, 7.0% w / v, 7.1% w / v, 7.2% w / v, 7.3% w / v, 7.4% w / v , 7.5% w / v, 7.6% w / v, 7.7% w / v, 7.8% w / v, 7.9% w / v, 8.0% w / v, 8.1% w / v, 8.2% w / v, 8.3% w / v or 8.4% w / v.
[0018] In one embodiment, acids that can form pharmaceutically acceptable salts with ketamine include hydrochloric acid, sulfuric acid, phosphoric acid, maleic acid, acetic acid, adipic acid, alginic acid, citric acid, aspartic acid, benzoic acid, benzenesulfonic acid, hydrogen sulfate, butyric acid, camphoric acid, camphorsulfonic acid, digluconic acid, fumaric acid, glycerophosphoric acid, stearyl heptanoic acid, hexanoic acid, hydrobromic acid, lactic acid, methanesulfonic acid, nicotinic acid, oxalic acid, bishydroxynaphthoic acid, pectic acid, persulfuric acid, 3-phenylpropionic acid, picric acid, pivalic acid, propionic acid, succinic acid, tartaric acid, thiocyanic acid, glutamic acid, p-toluenesulfonic acid, undecanoic acid, and mandelic acid.
[0019] In one embodiment, pharmaceutically acceptable salts can be formed with ketamine, including hydrochloride, sulfate, phosphate, maleate, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, fumarate, glycerophosphate, stearyl heptanoate, hexanoate, hydrochloride, hydrobromide, hydrogen iodide, lactate, methanesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, glutamate, bicarbonate, p-toluenesulfonate, undecanoate and mandelate.
[0020] In one embodiment, the concentration of the lower alcohol in the liquid preparation (i.e., the total of the two lower alkanols) is 5.5% w / v to 30% w / v. In another embodiment, the concentration of one lower alcohol in the liquid preparation is 6.0% w / v to 26.3% w / v. In yet another embodiment, the concentration of one lower alcohol in the liquid preparation is 6.1% w / v, 6.2% w / v, 6.3% w / v, 6.4% w / v, 6.5% w / v, 6.6% w / v, 6.7% w / v, 6.8% w / v, 6.9% w / v, 7.0% w / v, 8.0% w / v, 9.0% w / v, 10.0% w / v, 11.0% w / v, 12.0% w / v v, 13.0% w / v, 14.0% w / v, 15.0% w / v, 16.0% w / v, 17.0% w / v, 18.0% w / v, 19.0% w / v, 19.7% w / v , 20.0% w / v, 21.0% w / v, 22.0% w / v, 23.0% w / v, 24.0% w / v, 25.0% w / v, 26.0% w / v or 26.3% w / v.
[0021] In one embodiment, the pH of the liquid preparation is 2.5 to 7.5.
[0022] In one embodiment, the pH range of the liquid preparation is 4.0 to 7.0; in another embodiment, the pH range of the liquid preparation is 5.0 to 7.0; in another embodiment, the pH of the liquid preparation is 5.5 to 7.0; in another embodiment, the pH of the liquid preparation is 7.0 to 7.5; in another embodiment, the pH of the liquid preparation is 4.5 to 5.5; in another embodiment, the pH of the liquid preparation is 2.5, 2.6, 2.7, 2.8, 2.9, 3.0 , 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4 or 7.5.
[0023] In one embodiment, the liquid ketamine formulation further comprises a viscosity increasing agent.
[0024] In one embodiment, the viscosity increasing agent is one of liquid maltitol, xanthan gum, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, hydroxyethyl cellulose, polyvinyl alcohol, caprylic acid capric acid mono- and di-glycerides, carbomer or polyvinyl pyrrolidone, or a combination thereof.
[0025] In one embodiment, the ketamine liquid preparation further comprises one or more of the following excipients: a flavoring agent, an osmotic pressure regulator, and a preservative.
[0026] In one embodiment, the present application provides a ketamine liquid preparation, which further includes a flavoring agent. The flavoring agent can mask the peculiar smell that the pharmaceutical composition may have and improve its palatability, which is conducive to improving patient compliance. In one embodiment, the flavoring agent of the liquid preparation is saccharin sodium, fructose, sucralose, stevioside (or steviol glycoside), menthol, maltitol, xylitol, aspartame, sodium cyclamate, saccharin, neohesperidin, thaumatin, stevia or acesulfame potassium, or a combination thereof.
[0027] In one embodiment, the present application provides a ketamine liquid preparation, wherein the concentration of the flavoring agent is 0.5-2.5% w / v; in another embodiment, the concentration of the flavoring agent is 1.0-2.0% w / v; in yet another embodiment, the concentration of the flavoring agent is 1.0% w / v, 1.1% w / v, 1.2% w / v, 1.3% w / v, 1.4% w / v, 1.5% w / v, 1.6% w / v, 1.7% w / v, 1.8% w / v, 1.9% w / v or 2.0% w / v.
[0028] In one embodiment, the present application provides a ketamine liquid preparation, which further comprises a buffer. The buffer can be citric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, acetic acid, boric acid, sodium borate, succinic acid, tartaric acid, lactic acid, fumaric acid, malic acid, trisodium phosphate (trisodium phosphate dodecahydrate or TSP), sodium benzoate, benzoic acid, sodium hydroxide, potassium hydroxide, alkali metal carbonate, sodium carbonate, imidazole, pyrophosphate, sodium gluconate, sodium lactate, phosphoric acid, borate, bicarbonate, Tris-HCl, citrate, or a combination thereof.
[0029] The buffer described in the present application can maintain the pH of the liquid preparation within a stable range, which is beneficial to improving the stability of the solution preparation. The concentration of the buffer is 0.1-0.3% w / v; in one embodiment, the concentration of the buffer is 0.1-0.2% w / v; in another embodiment, the concentration of the buffer is 0.1-0.15% w / v; in another embodiment, the concentration of the buffer is 0.1% w / v, 0.11% w / v, 0.12% w / v, 0.13% w / v, 0.14% w / v, 0.16% w / v, 0.17% w / v, 0.18% w / v, 0.19% w / v, 0.20% w / v, 0.21% w / v, 0.22% w / v, 0.23% w / v, 0.24% w / v, 0.25% w / v, 0.26% w / v, 0.27% w / v, 0.28% w / v, 0.29% w / v, 0.30% w / v, 0.31% w / v, 0.32% w / v, 0.33% w / v, 0.34% w / v, 0.36% w / v, 0.37% w / v, 0.38% w / v, 0.39% w / v, 0.40% w / v, 0.41% w / v, 0.42% w / v, 0.43% w / v, 0.44% w / v, 0.45% w / v, 0.46% w / v, 0.47% w / v, 0.48% w / v, 0.49% w / v, 0.50% w / v .15% w / v, 0.16% w / v, 0.17% w / v, 0.18% w / v, 0.19% w / v, 0.2% w / v, 0.21% w / v, 0.22% w / v, 0.23% w / v, 0.24% w / v, 0.25% w / v, 0.26% w / v, 0.27% w / v, 0.28% w / v, 0.29% w / v, 0.3% w / v.
[0030] In one embodiment, the present application provides a ketamine liquid preparation, which further comprises an antioxidant. The antioxidant of the liquid preparation is ethylenediaminetetraacetic acid (EDTA, edetic acid) or its sodium salt (e.g., disodium edetic acid) or calcium salt, vitamin E, gallate, sodium bisulfite, ascorbic acid or its salt, butylated hydroxyanisole or tocopherol, or a combination thereof.
[0031] In one embodiment, the present application provides a ketamine liquid preparation, wherein the concentration of the antioxidant is 0.010-0.020% w / v; in another embodiment, the concentration of the antioxidant is 0.010-0.015% w / v.
[0032] In one embodiment, the ketamine liquid preparation further comprises a preservative. In one embodiment, the preservative is selected from one or more of methylparaben, ethylparaben, propylparaben, butylparaben, sodium methylparaben, sodium ethylparaben, sodium propylparaben, sodium butylparaben, sorbic acid, potassium sorbate, sodium sorbate, benzoic acid, sodium benzoate, benzyl alcohol, benzalkonium bromide, benzalkonium chloride, chlorobutanol, resorcinol and sodium ethylenediaminetetraacetate.
[0033] In one embodiment, the ketamine liquid preparation further comprises an osmotic pressure regulator. In one embodiment, the osmotic pressure regulator is selected from one or more of sodium chloride, potassium nitrate, boric acid and glucose; preferably, sodium chloride.
[0034] In one embodiment, the liquid ketamine formulation does not contain a preservative, an antioxidant, or a preservative and an antioxidant.
[0035] In a second aspect, the present application provides a ketamine liquid preparation, comprising ketamine or a pharmaceutically acceptable salt thereof, at least two lower alcohols, a viscosity enhancer, and water; the pH range of the liquid preparation is 2.5 to 7.5, and the content of ketamine in the liquid preparation is 0.7% w / v to 8.4% w / v.
[0036] In one embodiment, the types of the tackifiers and their contents with the lower alcohol are as described above.
[0037] In a third aspect, the present application provides a ketamine liquid preparation, comprising ketamine or a pharmaceutically acceptable salt thereof, at least two lower alcohols, a viscosity enhancer, a flavoring agent and water; the pH range of the liquid preparation is 2.5 to 7.5; the content of ketamine hydrochloride in the liquid preparation is 0.7% w / v to 8.4% w / v.
[0038] In one embodiment, the types of the viscosity enhancer and flavoring agent and their contents with the lower alcohol are as described above.
[0039] In one embodiment, in the liquid ketamine preparation provided herein, the flavoring agent is sodium saccharin.
[0040] In a fourth aspect, the present application provides the use of the above-mentioned ketamine liquid preparation in the preparation of a drug for preventing, alleviating or treating depression, wherein the drug can be used to treat major depression, unipolar depression, refractory depression, intractable depression, anxious depression, and bipolar depression.
[0041] In one embodiment, the present application provides a use of the above-mentioned ketamine liquid preparation in the preparation of a drug for preventing, alleviating or treating depression, wherein the liquid preparation is applied to the buccal membrane of the patient's oral cavity.
[0042] In a fifth aspect, the present application provides a method for preventing, alleviating or treating depression in a patient using the above-mentioned ketamine liquid preparation, comprising administering a therapeutically effective amount of the above-mentioned ketamine liquid preparation to the patient.
[0043] In one embodiment, the present application provides a method for preventing, alleviating or treating depression in a patient using the above-mentioned ketamine liquid preparation, wherein the depression is major depression, unipolar depression, refractory depression, intractable depression, anxious depression, or bipolar depression.
[0044] In one embodiment, the present application provides a method of using the above-mentioned ketamine liquid preparation to prevent, alleviate or treat depression in a patient, wherein the liquid preparation is applied to the buccal membrane of the patient's mouth.
[0045] In a sixth aspect, the present application provides the above-mentioned ketamine liquid preparation for use in preventing, alleviating or treating depression in patients, wherein the depression is major depression, unipolar depression, refractory depression, intractable depression, anxious depression, or bipolar depression.
[0046] In one embodiment, the ketamine liquid preparation provided herein is used for preventing, alleviating or treating depression in a patient, and the liquid preparation is applied to the buccal membrane of the oral cavity of a mammal.
[0047] In a seventh aspect, the present application provides a method for preparing the aforementioned ketamine liquid preparation, comprising the following preparation steps:
[0048] a) weighing a prescribed amount of ketamine or a pharmaceutically acceptable salt thereof, adding purified water, stirring thoroughly to dissolve, and then sequentially adding a prescribed amount of an optional flavoring agent such as saccharin sodium, stirring thoroughly to dissolve;
[0049] b) adding two lower alcohols and an optional viscosity enhancer in the prescription, stirring and dissolving them thoroughly;
[0050] c) adjusting the pH to a corresponding value with sodium hydroxide;
[0051] d) Transfer the solution to a specific volumetric flask and add water to the mark;
[0052] e) After the volume is fixed, the solution is filtered through a 0.45 μm filter membrane, and the filtrate is filled into a prefilled syringe to obtain the finished preparation.
[0053] The beneficial effects of this application are as follows:
[0054] (1) The ketamine liquid preparation provided in the present application can promote the penetration of the active substance into the oral mucosa by using a composition formed by two lower alcohols; and by further adding a viscosity enhancer, the retention time of the liquid preparation in the oral mucosa is increased.
[0055] (2) The ketamine liquid preparation provided in the present application is simple and easy to administer, which greatly increases patient compliance. Due to the small dosage and small volume, it can greatly reduce irritation to the mucous membrane and reduce the risk of abuse.
[0056] Unless otherwise indicated, all ingredient concentrations are expressed in weight / volume % (% w / v). As is commonly understood, % w / v values refer to the amount of a particular component or ingredient in a formulation. It is well known that equivalent concentrations can be expressed in different units. For example, a concentration of 0.1% w / v can also be expressed as 1 mg / ml solution.
[0057] Other features and advantages of the present application will be described in the following description, and partly become apparent from the description, or be understood by implementing the present application. Other advantages of the present application can be realized and obtained by the schemes described in the description and the drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] The accompanying drawings are used to provide an understanding of the technical solution of the present application and constitute a part of the specification. Together with the embodiments of the present application, they are used to explain the technical solution of the present application and do not constitute a limitation on the technical solution of the present application.
[0059] Figure 1 This is a diagram of the in vitro diffusion experiment of ketamine liquid preparation for this application;
[0060] Figure 2 Plasma pharmacokinetic profiles of esketamine preparations with different routes of administration are proposed for this application;
[0061] Figure 3 For this application, cerebrospinal fluid pharmacokinetic diagrams of esketamine preparations with different administration routes are proposed. DETAILED DESCRIPTION
[0062] The present application discloses a ketamine liquid preparation for oral mucosal administration and its use. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all deemed to be included in this application. The methods and applications of this application have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of this application to implement and apply the technology of this application. The reagents or instruments used in this application can all be purchased from the market.
[0063] Example 1
[0064] prescription:
[0065]
[0066] The preparation method comprises the following preparation steps:
[0067] a) weighing the prescribed amount of esketamine hydrochloride, adding it to 80% of the total mass of purified water, adding an appropriate amount of liquid maltitol and stirring to dissolve, and then adding the prescribed amount of fructose and stirring to dissolve;
[0068] b) Add the prescribed amount of anhydrous ethanol and glycerol and stir thoroughly to dissolve;
[0069] c) adjusting the pH to 4.5-5.5 with sodium hydroxide;
[0070] d) Transfer the solution to a specific volumetric flask and add liquid maltitol to make up to 20 ml;
[0071] e) After the volume is fixed, the solution is filtered through a 0.45 μm filter membrane, and the filtrate is filled into a 1 ml pre-filled syringe (purchased from Shandong Zibo Minkang Pharmaceutical Packaging Co., Ltd.), 1 ml / vial to obtain the finished preparation.
[0072] Example 2
[0073] prescription:
[0074]
[0075] The preparation method is the same as that of Example 1, and the pH is adjusted to 7.0-7.5.
[0076] Example 3
[0077] prescription:
[0078]
[0079] The preparation method is the same as that of Example 1, and the pH is adjusted to 4.5-5.5.
[0080] Example 4 Stability test of the ketamine liquid preparation of the present application
[0081] Ketamine liquid preparations are prone to produce the following two impurities during preparation and storage:
[0082]
[0083]
[0084] The above two impurities can be purchased through commercial channels.
[0085] The inventors conducted a long-term stability experiment on the samples prepared in Examples 1 and 2 in an environment of 25°C±2°C and RH60%±5%.
[0086] 1. Ketamine content detection method:
[0087] Determined by high performance liquid chromatography (General Rule 0512)
[0088] Chromatographic conditions: octadecylsilane bonded silica gel was used as filler; 0.95 g of sodium hexanesulfonate was dissolved in 1 L of a mixed solution of acetonitrile and water (acetonitrile: water = 25:75), and then 4 ml of glacial acetic acid was added and mixed as the mobile phase; the detection wavelength was 215 nm; the flow rate was 1.0 ml per minute; the column temperature was 30°C; and the injection volume was 20 μl.
[0089] 2. Methods for detecting ketamine-related substances:
[0090] Determined by high performance liquid chromatography (General Rule 0512).
[0091] Chromatographic conditions: octadecylsilane bonded silica gel as filler (Agela MP C18 4.6×150mm, 5μm or equivalent column efficiency); 25mM phosphate buffer (3.4g potassium dihydrogen phosphate, add 1000ml water to dissolve, adjust pH to 2.5 with phosphoric acid) as mobile phase A, acetonitrile as mobile phase B. Gradient elution was performed according to the table below, detection wavelength was 215nm; column temperature was 30℃; flow rate was 1.0ml per minute; injection volume was 20μl.
[0092] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 85 15 35 60 40 37 60 40 65 20 80 70 20 80 71 85 15 75 85 15
[0093] Table 3: Long-term test results of Examples 1-2
[0094]
[0095] From the results of the long-term test in Table 3, it can be seen that the drug preparation obtained in the present application is placed at room temperature for up to 3 months, the total impurities of the ketamine liquid preparation do not exceed 0.5%, and the maximum single impurity does not exceed 0.3%, and its quality still meets the quality standards and is stable.
[0096] Example 5 In vitro diffusion test of the ketamine liquid preparation of the present application
[0097] This study used the Franz diffusion cell method and selected the phospholipid biomimetic barrier (Bionic membrane) simulates oral mucosa, and PBS buffer is used as the diffusion medium; after the diffusion cell reaches 37° C., 0.5 ml of artificial saliva is first added above the bionic membrane, and then 0.2 ml of the solution prepared in Example 1 and Example 2 is added, and in vitro permeation tests are performed respectively, and the sampling time points are 10 min, 20 min, 30 min, 45 min, 60 min, 90 min, 120 min, and 180 min. 1 ml of sample is taken at each time point, and the content is detected by liquid phase.
[0098] Table 4: In vitro permeation results of Examples 1-2
[0099]
[0100]
[0101] Comparative Example 1 Esketamine hydrochloride nasal spray (prepared according to patent CN 111297803 A)
[0102] Prescription ingredients
[0103]
[0104] Product specifications: Each spray contains 14.00 mg of esketamine
[0105] The preparation method comprises the following preparation steps:
[0106] a) Weigh the prescribed amount of dexketamine hydrochloride, add a certain amount of purified water, stir thoroughly to dissolve, and then sequentially add the prescribed amount of edetate disodium and citric acid, stir thoroughly to dissolve;
[0107] b) adjusting the pH to 4.5 with sodium hydroxide;
[0108] c) Transfer the solution to a specific volumetric flask and add water to the mark;
[0109] d) After the volume is fixed, the solution is filtered through a 0.45 μm filter membrane and the filtrate is filled as required.
[0110] Test Example 1 In vivo pharmacokinetic experiment
[0111] 1. Experimental Grouping
[0112] Table 5: Animal grouping
[0113]
[0114]
[0115] 2. Experimental plan
[0116] This experiment uses Beagle dogs, 7.80kg to 9.42kg, 3 per group. After the animals arrive at the institution, qualified personnel will conduct health checks on the animals, and carry out adaptive feeding management and related domestication for at least 14 days. Qualified animals that meet the experimental requirements will be selected for the experiment.
[0117] Dosage:
[0118] Animals in Group 1: Fix the animal, tilt the animal's head upward so that the nasal cavity is horizontal, and extend about 1 cm into the nasal cavity. Spray 1 spray (0.1 mL / spray) into the animal's nasal cavity through one nostril, and each animal should use the same nostril for dosing. Hold the dog's head horizontally for 2 minutes, and observe whether the drug flows out. After confirming that there is no drug outflow, put the animal back into the cage. Note that the speed of drug administration should not be too fast to avoid choking into the trachea or outflow of the drug solution, resulting in a reduced amount of dripping and affecting the test results.
[0119] Animals in groups 2-4: Dogs were anesthetized by intramuscular injection of Zoltek 50 (dosage 8-10 mg / kg, concentration 50 mg / mL). The tongue of the dog was fixed under anesthesia, and the dog's head was placed on the operating table. A test drug preparation was taken, the lower cap was unscrewed, the syringe was placed at the buccal administration site, and the piston was pushed to allow the drug to flow out for 5 minutes. Note that the drug was administered to the left or right buccal membrane. The dog drooled and could not swallow 15 minutes after administration. The saliva was not processed and flowed out naturally. At the same time, the area of the towel wetted by saliva was recorded. The operation of all dogs administered with buccal membranes should be consistent.
[0120] Comparative Example 1 adopts unilateral nasal administration, the dosage is 0.1 ml / mouse (1 spray), and the dosage is 14 mg; Experimental Example 3 adopts unilateral buccal liquid administration, the dosage is 0.25 ml / mouse, and the dosage is 14 mg.
[0121] At each time point, about 0.3 mL of whole blood was collected from the subcutaneous vein of the forelimb or hindlimb of each group of animals. The time points for blood collection were: 0 min (before administration), 2 min, 5 min, 10 min, 15 min, 30 min, 60 min, 2 h, 4 h, 6 h, and 8 h.
[0122] Plasma sample processing: Before blood collection, place the centrifuge tube with EDTA-K2 in an ice box filled with crushed ice; add the collected blood to the centrifuge tube, manually invert at least 5 times, and store it in an ice box filled with crushed ice; centrifuge at 2000g for 10 minutes at 2-8°C, and complete the centrifugation within 1 hour after blood collection. The centrifuged plasma is transferred to a tube with a new label, temporarily stored and transported in an ice box filled with crushed ice, and stored below -60°C. Watson LIMS 7.5 system is used to manage samples.
[0123] Cerebrospinal fluid sample collection: About 0.2 mL of cerebrospinal fluid was collected from the lumbar vertebrae or foramen magnum of each group of animals at each time point. Cerebrospinal fluid was collected at 0 min (before administration), 15 min, 1 h, and 4 h. After sample collection, it was temporarily stored and transported in an ice box filled with crushed ice and stored below -60°C. Watson LIMS 7.5 system was used to manage the samples.
[0124] 3. Experimental results
[0125] Table 6: Concentration-time changes of esketamine in plasma of Beagle dogs with different administration routes of two preparations
[0126]
[0127] Table 7: Concentration-time changes of esketamine in the cerebrospinal fluid of Beagle dogs with different administration routes of two preparations
[0128]
[0129] Table 8: Pharmacokinetic results of esketamine in Beagle dog plasma after different administration routes of two preparations
[0130]
[0131] Table 9: Results of the pharmacokinetic study of esketamine in the cerebrospinal fluid of Beagle dogs with different administration routes of two preparations
[0132]
[0133] From Table 8 and Figure 2 It can be seen that for plasma samples, among the different administration routes of esketamine hydrochloride, the buccal administration group (Example 3) has a T of 1.34, compared with the nasal administration group (Comparative Example 1). max The average C max The data show that compared with the nasal administration group (Comparative Example 1), the buccal administration group (Example 3) of the buccal solution has a C max The AUC of the buccal administration group (Example 3) of the buccal solution was significantly increased, indicating that the drug absorption of the buccal solution of esketamine hydrochloride in the present application is higher than that of the nasal administration group (Comparative Example 1). last This result is consistent with C max The results are consistent with those of , which further illustrates that the in vivo drug absorption of esketamine hydrochloride buccal solution administered by buccal membrane of the present application is higher than that of nasal administration.
[0134] From Table 9 and Figure 3 It can be seen that for cerebrospinal fluid samples, among the different administration routes of esketamine hydrochloride, the buccal administration group (Example 3) has a T of 1.34 mmol / l and a T of 1.33 mmol / l. max The average C max The data show that in the cerebrospinal fluid samples, compared with the nasal administration group (Comparative Example 1), the buccal administration group (Example 3) has a higher Cmax The AUC of the buccal administration group (Example 3) of the buccal solution was significantly increased, indicating that the drug absorption of the buccal solution of esketamine hydrochloride in the present application is higher than that of the nasal administration group (Comparative Example 1). last This result is consistent with that of C max The results are consistent with those of , which further illustrates that the in vivo drug absorption of esketamine hydrochloride buccal solution administered by buccal membrane of the present application is higher than that of nasal administration.
[0135] In summary, the onset time of the two esketamine hydrochloride preparations by different administration routes is similar, about 0.25h, but the in vivo drug absorption of esketamine hydrochloride via buccal solution and buccal membrane is significantly higher than that via nasal administration.
[0136] The technical solution of the present application can also be used for the buccal liquid and buccal membrane delivery system of R-ketamine, ketamine or pharmaceutically acceptable salts, and the purpose of the present invention can be achieved by adjusting or changing the content of active ingredients, the types and dosages of pharmaceutical excipients, etc.
[0137] Although the embodiments disclosed in this application are as above, the contents described are only embodiments adopted to facilitate understanding of this application and are not intended to limit this application. Any technician in the field to which this application belongs can make any modifications and changes in the form and details of implementation without departing from the spirit and scope disclosed in this application, but the scope of protection of this application shall still be based on the scope defined in the attached claims.
Claims
1. A ketamine liquid preparation for oral mucosal administration, comprising ketamine or a pharmaceutically acceptable salt thereof at a concentration of 0.5% w / v to 8.5% w / v, at least two lower alcohols, and water.
2. The ketamine liquid preparation according to claim 1, wherein The ketamine may be one of its two enantiomers, esketamine or R-ketamine, or a mixture of the two.
3. The ketamine liquid preparation according to claim 1, wherein The concentration of ketamine in the liquid preparation is 0.7% w / v to 8.4% w / v; preferably, 1.4% w / v to 6.8% w / v; more preferably, 1.4% w / v to 6.4% w / v.
4. The ketamine liquid preparation according to claim 1, wherein The lower alcohol is selected from ethanol, propanol, isopropanol, butanol, isobutanol, ethylene glycol, propylene glycol, glycerol, sorbitol, mannitol, butylene glycol, and hexylene glycol.
5. The ketamine liquid preparation according to claim 4, wherein The two lower alcohols are ethanol and glycerol, or sorbitol and glycerol.
6. The ketamine liquid preparation according to claim 5, wherein: The weight ratio of ethanol to glycerol is (0.5 to 100):1, preferably 3.95:1.32; or the weight ratio of sorbitol to glycerol is (0.5 to 100):1, preferably 4.8:1.
32.
7. The ketamine liquid preparation according to any one of claims 1 to 6, wherein The total concentration of the lower alcohols is 5.5% w / v to 30% w / v, preferably, 6.0% w / v to 26.3% w / v.
8. The ketamine liquid preparation according to any one of claims 1 to 7, wherein The pH range of the liquid preparation is 2.5 to 7.5; preferably, 4.0 to 7.0; more preferably, 5.0 to 7.
0.
9. The ketamine liquid preparation according to any one of claims 1 to 8, further comprising a viscosity enhancer.
10. The ketamine liquid preparation according to claim 9, wherein The viscosity enhancer is one of liquid maltitol, xanthan gum, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, hydroxyethyl cellulose, polyvinyl alcohol, caprylic acid capric acid mono- and diglycerides, carbomer and polyvinyl pyrrolidone, or a combination thereof.
11. The ketamine liquid preparation according to any one of claims 1 to 8, further comprising one or more of the following excipients: a buffer, a flavoring agent, an antioxidant, an osmotic pressure regulator, and a preservative.
12. The ketamine liquid preparation according to claim 11, wherein The flavoring agent is one of saccharin sodium, fructose, sucralose, stevioside, menthol, maltitol, xylitol, aspartame, sodium cyclamate, saccharin, neohesperidin, thaumatin, stevia and acesulfame potassium, or a combination thereof; and / or The buffer can be citric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, acetic acid, boric acid, sodium borate, succinic acid, tartaric acid, lactic acid, fumaric acid, malic acid, trisodium phosphate (trisodium phosphate dodecahydrate or TSP), sodium benzoate, benzoic acid, sodium hydroxide, potassium hydroxide, alkali metal carbonate, sodium carbonate, imidazole, pyrophosphate, sodium gluconate, sodium lactate, phosphoric acid, borate, bicarbonate, Tris-HCl, citrate, or a combination thereof; and / or The antioxidant is ethylenediaminetetraacetic acid or its sodium salt or calcium salt, vitamin E, gallate, sodium bisulfite, ascorbic acid or its salt, butylated hydroxyanisole or tocopherol, or a combination thereof; and / or The osmotic pressure regulator is selected from one or more of sodium chloride, potassium nitrate, boric acid and glucose; and / or The preservative is selected from one or more of methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, sodium propyl parahydroxybenzoate, sodium butyl parahydroxybenzoate, sorbic acid, potassium sorbate, sodium sorbate, benzoic acid, sodium benzoate, benzyl alcohol, benzalkonium bromide, benzalkonium chloride, chlorobutanol, resorcinol and sodium ethylenediaminetetraacetate.
13. The ketamine liquid preparation according to any one of claims 1 to 8, wherein The liquid preparation does not contain preservatives, antioxidants, or preservatives and antioxidants.
14. Use of the ketamine liquid preparation according to any one of claims 1 to 13 in the preparation of a drug for preventing, alleviating or treating depression.
15. The use according to claim 14, wherein The depression is major depression, unipolar depression, refractory depression, intractable depression, anxious depression, or bipolar depression.
16. The use according to claim 14 or 15, wherein The liquid formulation is applied to the buccal membranes of the patient's oral cavity.
